Exbio — Research products — Antibodies — CD and related antigens — Anti-Hu CD3 Purified Low Endotoxin

Anti-Hu CD3 Purified Low Endotoxin

Regulatory status

RUO

Antigen

CD3

Clone

OKT3

Format

Purified Low Endotoxin

Reactivity

Human

Application

FC (QC tested), IHC-F, FUNC

Variant

0.1 mg

12-631-C100

In stock

147.40 USD

1.0 mg

12-631-M001

In stock

440.00 USD

Variant

0.1 mg

12-631-C100

In stock

147.40 USD

1.0 mg

12-631-M001

In stock

440.00 USD

Contact distributor

Product details

Description

Images

References

SDS download

Isotype

Mouse IgG2a

Specificity

The mouse monoclonal antibody OKT3 recognizes an extracellular epitope on CD3 antigen of the TCR/CD3 complex on mature human T cells. This antibody, also known as Orthoclone OKT3 or Muromonab-CD3, has been extensively used as a drug for therapy of acute, glucocorticoid resistant rejection of allogenic renal, heart and liver transplants. It has also been investigated for use in treating T-cell acute lymphoblastic leukemia.

Workshop

HLDA VI: WS Code T6T-R3

Application

FC (QC tested), IHC-F, FUNC

Application details

Functional application: counteracting both generation and function of effector T cells.
Flow cytometry: Recommended dilution: 1 μg/ml.

Reactivity

Human

Immunogen

human T cells

Concentration

1 mg/ml

Preparation

Purified by protein-A affinity chromatography.

Formulation

Phosphate buffered saline (PBS), pH 7.4

Storage and handling

Store at 2-8°C. Do not freeze.

The product is intended For Research Use Only. Diagnostic or therapeutic applications are strictly forbidden. Products shall not be used for resale or transfer to third parties either as a stand-alone product or as a manufacture component of another product without written consent of EXBIO Praha, a.s. EXBIO Praha, a.s. will not be held responsible for patent infringement or any other violations of intellectual property rights that may occur with the use of the products. Orders for all products are accepted subject to the Term and Conditions available at www.exbio.cz. EXBIO, EXBIO Logo, and all other trademarks are property of EXBIO Praha, a.s.

Other names

CD3E, T3E, TCRE

Antigen description

CD3 complex is crucial in transducing antigen-recognition signals into the cytoplasm of T cells and in regulating the cell surface expression of the TCR complex. T cell activation through the antigen receptor (TCR) involves the cytoplasmic tails of the CD3 subunits CD3 gamma, CD3 delta, CD3 epsilon and CD3 zeta. These CD3 subunits are structurally related members of the immunoglobulins super family encoded by closely linked genes on human chromosome 11. The CD3 components have long cytoplasmic tails that associate with cytoplasmic signal transduction molecules. This association is mediated at least in part by a double tyrosine-based motif present in a single copy in the CD3 subunits. CD3 may play a role in TCR-induced growth arrest, cell survival and proliferation. The CD3 antigen is present on 68-82% of normal peripheral blood lymphocytes, 65-85% of thymocytes and Purkynje cells in the cerebellum. It is never expressed on B or NK cells. Decreased percentages of T lymphocytes may be observed in some autoimmune diseases.

Entrez Gene ID 916

UniProt ID P07766

Flow cytometry surface staining pattern of human peripheral whole blood stained using anti-human CD3 (OKT3) purified antibody (low endotoxin, concentration in sample 1 μg/ml) GAM APC.

Separation of human CD3 positive lymphocytes (red-filled) from neutrophil granulocytes (black-dashed) in flow cytometry analysis (surface staining) of human peripheral whole blood stained using anti-human CD3 (OKT3) purified antibody (low endotoxin, concentration in sample 1 μg/ml) GAM APC.

General references:

Huang Y, Wange RL: T cell receptor signaling: beyond complex complexes. J Biol Chem. 2004 Jul 9;279(28):28827-30.
PubMed

Alarcón B, Swamy M, van Santen HM, Schamel WW: T-cell antigen-receptor stoichiometry: pre-clustering for sensitivity. EMBO Rep. 2006 May;7(5):490-5.
PubMed

Kuhns MS, Davis MM, Garcia KC: Deconstructing the form and function of the TCR/CD3 complex. Immunity. 2006 Feb;24(2):133-9.
PubMed

Product specific references:

Gordon PR, Leimig T, Mueller I, Babarin-Dorner A, Holladay MA, Houston J, Kerst G, Geiger T, Handgretinger R: A large-scale method for T cell depletion: towards graft engineering of mobilized peripheral blood stem cells. Bone Marrow Transplant. 2002 Jul;30(2):69-74.
PubMed

Li T, Wong VK, Yi XQ, Wong YF, Zhou H, Liu L: Matrine induces cell anergy in human Jurkat T cells through modulation of mitogen-activated protein kinases and nuclear factor of activated T-cells signaling with concomitant up-regulation of anergy-associated genes expression. Biol Pharm Bull. 2010 Jan;33(1):40-6.
PubMed

Undale AH, van den Elsen PJ, Celis E: Antigen-independent acquisition of MHC class II molecules by human T lymphocytes. Int Immunol. 2004 Oct;16(10):1523-33.
PubMed

Quintana A, Schwindling C, Wenning AS, Becherer U, Rettig J, Schwarz EC, Hoth M: T cell activation requires mitochondrial translocation to the immunological synapse. Proc Natl Acad Sci U S A. 2007 Sep 4;104(36):14418-23.
PubMed

Trushin SA, Bren GD, Asin S, Pennington KN, Paya CV, Badley AD. Human immunodeficiency virus reactivation by phorbol esters or T-cell receptor ligation requires both PKCalpha and PKCtheta. J Virol. 2005 Aug;79(15):9821-30.
PubMed

Lang P, Handgretinger R, Niethammer D, Schlegel PG, Schumm M, Greil J, Bader P, Engel C, Scheel-Walter H, Eyrich M, Klingebiel T: Transplantation of highly purified CD34+ progenitor cells from unrelated donors in pediatric leukemia. Blood. 2003 Feb 15;101(4):1630-6.
PubMed

Schlegel PG, Eyrich M, Bader P, Handgretinger R, Lang P, Niethammer D, Klingebiel T: OKT-3-based reconditioning regimen for early graft failure in HLA-non-identical stem cell transplants. Br J Haematol. 2000 Nov;111(2):668-73.
PubMed

Smith SL: Ten years of Orthoclone OKT3 (muromonab-CD3): a review. J Transpl Coord. 1996 Sep;6(3):109-19; quiz 120-1.
PubMed

Katayose Y, Kudo T, Suzuki M, Shinoda M, Saijyo S, Sakurai N, Saeki H, Fukuhara K, Imai K, Matsuno S: MUC1-specific targeting immunotherapy with bispecific antibodies: inhibition of xenografted human bile duct carcinoma growth. Cancer Res. 1996 Sep 15;56(18):4205-12.
PubMed

Guven H, Gilljam M, Chambers BJ, Ljunggren HG, Christensson B, Kimby E, Dilber MS: Expansion of natural killer (NK) and natural killer-like T (NKT)-cell populations derived from patients with B-chronic lymphocytic leukemia (B-CLL): a potential source for cellular immunotherapy. Leukemia. 2003 Oct;17(10):1973-80.
PubMed